Maricann Group (CNSX:MARI – Free Report) had its price objective raised by National Bankshares from $7.50 to $11.00 in a research report report published on Friday morning,BayStreet.CA reports. The brokerage currently has an outperform rating on the stock.
Separately, BMO Capital Markets boosted their price target on shares of Maricann Group from $7.00 to $9.50 and gave the company an “outperform” rating in a research note on Friday.
View Our Latest Research Report on MARI
Maricann Group Price Performance
Maricann Group Company Profile
Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients.
Featured Stories
- Five stocks we like better than Maricann Group
- Top Biotech Stocks: Exploring Innovation Opportunities
- The Apple Comeback Will Be Better Than the Setback
- Best Aerospace Stocks Investing
- How a Government Loan Changes the Game for Plug Power
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Qualcomm’s Hold Rating Misses Strong Growth Story
Receive News & Ratings for Maricann Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maricann Group and related companies with MarketBeat.com's FREE daily email newsletter.
